---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036006"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:35:29.445224+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health FY 2023 revenue down 36% to $1.2M; net loss narrows to $8.2M

## Summary
- Revenue $1.2M (-36% YoY) on 52% fewer unit sales; ASP up 46%.
- Net loss improved to $8.2M from $10.1M; cash $3.4M, no debt.
- Raised $7.9M via two public offerings in 2023; executed 1-for-100 reverse split and regained Nasdaq compliance.
- Completed enrollment for VNS pilot study in Feb 2024; results pending.
- Named to Fast Company's Most Innovative Companies 2023 in Medical Device.

## SEC filing metadata
- accession: 0000950170-24-036006
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/0000950170-24-036006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/tivc-20240325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036006
- JSON: https://secwatch.observer/filing/0000950170-24-036006.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036006.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported the year ending December 31, 2023 results: revenue $1.2M, net income net loss was $8.2M.
  - Period: the year ending December 31, 2023
  - Revenue: $1.2M
  - Net income: net loss was $8.2M
  - Result: reported results
  source text: and Global Health & Pharma (GHP) named Tivic Health the Most Pioneering Bioelectronic Medicine Company. 2023 Financial Performance • Revenue (net of returns) for 2023 was $1.2M compared to $1.8M for the year ended December 31, 2022. The decrease of $664 thousand, or 36%, was due to a 52% decrease in ClearUP unit sales, offset by 46% higher average
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017024036006/0000950170-24-036006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.